SCHEMBL23970799

SCHEMBL23970799

Cc1ncc(NC(=O)OC(C)(C)C)cc1OCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.50
PTGER1 P34995 1/20 0.50
BRD4 O60885 1/20 0.45
RORC P51449 4/20 0.45
CYP11B1 P15538 1/20 0.44
CYP11B2 P19099 1/20 0.44
SGMS2 Q8NHU3 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
PDK1 Q15118 1/20 0.44
PDK2 Q15119 1/20 0.44
PDK3 Q15120 1/20 0.44
PDK4 Q16654 1/20 0.44
LRRK2 Q5S007 1/20 0.43
SIRT2 Q8IXJ6 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
TOP2A P11388 1/20 0.43
TOP2B Q02880 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30159014 1.00 CYP2C9 (0.50) CYP2C9PTGER1BRD4RORCCYP11B1
SCHEMBL4032867 0.80 NPC1 (0.57) CYP2C9PTGER1SMN1; SMN2NPC1RAB9A
SCHEMBL10152859 0.80 ALDH1A1 (0.57) CYP2C9PTGER1SMN1; SMN2NPC1RAB9A
SCHEMBL20400859 0.80 NPC1 (0.51) CYP2C9PTGER1CYP11B1CYP11B2SGMS2
SCHEMBL18888156 0.80 CYP2C9 (0.46) CYP2C9PTGER1BRD4SMN1; SMN2NPC1
SCHEMBL28950632 0.79 CYP2C9 (0.46) CYP2C9PTGER1BRD4SMN1; SMN2NPC1
SCHEMBL13007025 0.79 TOP2A (0.50) CYP2C9PTGER1BRD4SGMS2SMN1; SMN2
SCHEMBL30158816 0.79 CYP2C9 (0.46) CYP2C9PTGER1BRD4SMN1; SMN2NPC1
SCHEMBL7342794 0.79 BRD4 (0.68) CYP2C9PTGER1BRD4SGMS2NPC1
SCHEMBL5235275 0.79 BCHE (0.50) CYP2C9PTGER1SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115551862-B Macrocyclic inhibitors of peptidyl arginine deiminase 吉利德科学公司 2024-04-12 CN disclosed
US-20230002412-A1 INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. 2023-01-05 US disclosed
CN-115551862-A Macrocyclic inhibitors of peptidyl arginine deiminase 吉利德科学公司 2022-12-30 CN disclosed
WO-2021222353-A1 MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002412-A1 INHIBITORS OF PEPTIDYLARGININE DEIMINASES PADI4, PADI2, PADI1 CYP2C9 4403/4885PTGER1 3602/4885BRD4 773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.